The Project: Every Child Protocol: A Registry Eligibility Screening Biology and Outcome Study

S
Sandeep Batra, MD

Primary Investigator

Overview

This research trial studies the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.

Description

The purpose of this study is to maintain a Childhood Cancer Registry for infants, children, adolescents, and young adults with cancer; to utilize clinical and biological data to help determine eligibility or stratification, based on childhood cancer disease classification schemas, for potential enrollment of research subjects onto Children's Oncology Group (COG) therapeutic clinical trials; to develop a well annotated childhood cancer biobank for current and future research through the collection of biospecimens (at diagnosis, time of progression, time of recurrence and/or post-mortem), including tumor, host and when feasible parental germline deoxyribonucleic acid (DNA); and key clinical data, including presentation, diagnostic, staging, summary treatment, and outcome information, from every child diagnosed with cancer at COG institutions; and to allow use of registry data for permission to be contacted in the future to consider participating in non-therapeutic and prevention research studies involving the child or their parents.

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Central Nervous System Neoplasm,Childhood Lymphoma,Childhood Relapsed Solid Tumor
  • Age: - 25 Years
  • Gender: All

Inclusion Criteria
In order to be eligible to take part in this trial, patients must meet the following criteria:

  • Enrollment can occur at any time after disease presentation including at time of disease progression or recurrence; for patients who are to be enrolled on COG therapeutic studies, enrollment on APEC14B1 must occur prior to enrollment onto the therapeutic trial
  • Subjects must be =< 25 years of age at time of original diagnosis, except for patients who are being screened specifically for eligibility onto a COG (or COG participating National Clinical Trials Network (NCTN) ) therapeutic study, for whom there is a higher upper age limit
For a full list of participation criteria, please visit clinicaltrials.gov.
Additional Information:
Participants will not be paid for their participation.

Updated on 07 Jul 2023. Study ID: 1511914729 (PHO-COG-FALLON-APEC14B1)

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center